Oracle Puts a Doctor on the Board: Inside the High-Stakes Pivot to AI and Cloud
13.05.2026 - 13:53:39 | boerse-global.de
Oracle is engineering one of the most profound makeovers in enterprise technology, but the market is still digesting the risks. The software giant is slashing roughly 30,000 jobs while committing $50 billion to cloud and AI infrastructure this year alone, and it just added a top medical executive to its board to deepen its healthcare push. The stock, after a strong monthly run, has pulled back as macro jitters hit tech valuations.
The new board member is Dr. Tomislav Mihaljevic, CEO of the renowned Cleveland Clinic. He joined the board in early May 2026 as the thirteenth director, with a formal shareholder vote scheduled for November. The appointment signals Oracle's ambition to embed its cloud and AI solutions deeper into the medical sector, an area where Mihaljevic's network and operational expertise could prove valuable.
Inflation bites again
Macro forces have dominated near-term sentiment. The US Consumer Price Index for April came in at 3.8%, slightly above expectations, pushing the yield on the 10-year Treasury to 4.46%. For growth-dependent tech stocks, that is a classic headwind. Oracle's shares slipped to €159.20 in recent trading, down about 3.6% over seven days. Over the past month, however, the stock still shows a 20% gain, suggesting the latest dip is more consolidation than a reversal.
Radical restructuring
Behind the scenes, Oracle is undergoing a deep transformation. Reports indicate the company plans to eliminate around 30,000 positions — roughly 18% of its global workforce — as part of a cost-cutting drive to free up resources for AI expansion. The investment side is equally aggressive: capital expenditure for the current fiscal year is budgeted at $50 billion, aimed at scaling cloud and AI capacity.
Should investors sell immediately? Or is it worth buying Oracle?
The bet is backed by a record order pipeline. The company's backlog stands at $553 billion, driven largely by multiyear cloud contracts for compute-intensive AI workloads. Recent results support the momentum: third-quarter revenue rose nearly 22% to $17.19 billion, while adjusted earnings per share of $1.79 beat consensus estimates. For the fourth quarter, management expects adjusted EPS between $1.96 and $2.00 and revenue growth of 19% to 21% year over year.
Analysts stay bullish
Despite the macro headwinds, several Wall Street firms remain upbeat. Wedbush lifted its price target to $275 with an "Outperform" rating, arguing that Oracle is a structural beneficiary of AI infrastructure buildout. Oppenheimer went a step further, raising its target to $235 and naming the stock a "Top Pick," citing sustained demand for technology infrastructure. Institutional investors appear to agree, holding more than 42% of Oracle's equity.
The company also extended a key partnership with Samsung, which will standardize its global software development on Oracle Java SE. That deal adds another long-term revenue stream to an already loaded pipeline.
Oracle at a turning point? This analysis reveals what investors need to know now.
The next major checkpoint comes in June, when Oracle reports its fiscal fourth-quarter results. The numbers will offer the clearest look yet at whether the company's massive spending on AI infrastructure is translating into the growth needed to justify its valuation.
Ad
Oracle Stock: New Analysis - 13 May
Fresh Oracle information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Oracle Aktien ein!
Für. Immer. Kostenlos.
